CNS Tumor Clinical Trial
Official title:
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06036394 -
Artificial Intelligence in CNS Radiation Oncology
|
||
| Withdrawn |
NCT05222165 -
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03838042 -
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05300113 -
Artificial Intelligence Neuropathologist
|
||
| Completed |
NCT04334239 -
Effectiveness of Care in Certified Cancer Centres in Germany
|
||
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
| Withdrawn |
NCT05952687 -
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
|
Phase 1 | |
| Terminated |
NCT02988726 -
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
|
Phase 2 | |
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Not yet recruiting |
NCT06441331 -
Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
|
Phase 1 | |
| Recruiting |
NCT04706676 -
Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer
|
N/A | |
| Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT05982691 -
Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors
|
||
| Recruiting |
NCT04732065 -
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02684838 -
Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
|
||
| Recruiting |
NCT05480904 -
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
|